Basic Trial Information
|Phase II||Treatment||Completed||18 and over||NCI, Other||CDR0000502192|
RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well trabectedin works in treating patients with advanced, persistent, or recurrent leiomyosarcoma of the uterus.
Further Study Information
- Determine the antitumor activity of trabectedin, as measured by frequency and duration of objective response, in patients with advanced, persistent, or recurrent uterine leiomyosarcoma.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: This is a nonrandomized, multicenter study.
Patients receive trabectedin IV continuously over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve a confirmed complete response may receive at least 2 additional courses.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.
- Histologically confirmed uterine leiomyosarcoma
- Histological confirmation of original primary tumor required
- Advanced, persistent, or recurrent disease
- Documented disease progression
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, and MRI OR ≥ 10 mm by spiral CT scan
- Tumors within a previously irradiated field are considered nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiotherapy
- Ineligible for a higher priority GOG protocol (i.e., any active phase III GOG protocol for the same patient population)
- GOG performance status 0-2
- Fertile patients must use effective contraception
- Platelet count ≥ 100,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 1.5 times ULN
- No active infection requiring antibiotics (except for patients with uncomplicated UTI)
- No neuropathy (sensory or motor) > grade 1
- No other invasive malignancy within the past 5 years except for nonmelanoma skin cancer
- No known active liver disease or hepatitis
- Must be willing/able to have a central venous catheter
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior surgery, radiotherapy, or other therapy
- No prior cancer treatment that would preclude study therapy
- No prior cytotoxic chemotherapy or biologic therapy for uterine sarcoma
- No prior chemotherapy for any abdominal or pelvic tumor within the past 5 years
- Prior adjuvant chemotherapy for localized breast cancer is allowed provided it was completed more than 3 years ago and there is no evidence of recurrent or metastatic disease
- No prior radiotherapy within the past 5 years to any portion of the abdominal cavity or pelvis other than for treatment of uterine sarcoma
- Prior radiotherapy for localized cancer of the breast, head and neck or skin is allowed, provided that it was completed more than 3 years ago and there is no evidence of recurrent or metastatic disease
- At least 1 week since prior hormonal therapy for the malignancy (continuation of hormone replacement therapy is permitted)
- No concurrent amifostine or other protective agents
Trial Lead Organizations/Sponsors
Gynecologic Oncology Group
- National Cancer Institute
Bradley J. Monk, Study Chair
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00379145
ClinicalTrials.gov processed this data on February 27, 2015
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.